Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice

Pharmacological Reports

Volumn 64, Issue 6, 2012, Pages 1326-1336

  Kumar, Anil ^a   Vashist, Aditi ^a   Kumar, Puneet ^a   Kalonia, Harikesh ^a   Mishra, Jitendriya ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Anxiety; Atorvastatin; Chronic fatigue stress; Fluvastatin; Mitochondrial enzyme complexes; Oxidative stress; Running wheel activity test session (RWATS)

Indexed keywords

ATORVASTATIN; CATALASE; FLUINDOSTATIN; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MITOCHONDRIAL ENZYME; NITRATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ACTIVITY; DRUG DOSE COMPARISON; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; MAZE TEST; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; RUNNING;

EID: 84873734305     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70930-1     Document Type: Article

References (62)

1. Afari N, Buchwald D: Chronic fatigue syndrome: a review. Am J Psychiatry, 2003, 160, 2, 221-236. (Pubitemid 41110447)
2. Aguiar AS Jr, Tuon T, Pinho CA, Silva LA, Andreazza AC, Kapczinski F, Quevedo J et al.: Mitochondrial IV complex and brain neurothrophic derived factor responses of mice brain cortex after downhill training. Neurosci Lett, 2007, 426, 171-174. (Pubitemid 47500183)
3. Aviram M, Rosenblat M, Bisgaier CL, Newton RS: Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis, 1998, 138, 271-280. (Pubitemid 28314098)
4. Berman SB, Hastings TG: Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem, 1999, 73, 1127-1137. (Pubitemid 29395471)
5. Chapman D, Newton M, Sacco P, Nosaka K: Greater muscle damage induced by fast versus slow velocity eccentric exercise. Int J Sports Med, 2006, 27, 591-598. (Pubitemid 44221067)
6. Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL: Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol, 1997, 30, 569-575. (Pubitemid 27339340)
7. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004, 109, Suppl III, 39-43.
8. Davignon J, Jacob RF, Mason RP: The antioxidant effects of statins. Coron Artery Dis, 2004, 15, 251-258. (Pubitemid 39061608)
9. Demetree E, Bastide L, D'Haese A, Smet K, De Meirleir K, Tiev KP, Englebienne P, Lebleu B: Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem, 2002, 277, 35746-35751.
10. Dhir A, Kulkarni SK: Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. Pharmacol Biochem Behav, 2008, 89, 563-571.
11. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys, 1959, 82, 70-77.
12. Englebienne P, Fremont M, De Meirleir K, Verhas M: How can the IFN/2-5A pathway promote and block apoptosis in immune cells: the chronic fatigue syndrome case. Eur J Biochem, 2003, 270, Suppl 1, 96-97.
13. Evans WJ, Lambert CP: Physiological basis of fatigue. Am J Phys Med Rehabil, 2007, 86, S29-46. (Pubitemid 46352653)
14. Floris S, Blezer EL, Schreibelt G, Dopp E, van der Pol SM, Schadee-Eestermans IL, Nicolay K et al.: Bloodbrain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain, 2004, 127, 616-627. (Pubitemid 38295477)
15. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med, 1994, 121, 953-959. (Pubitemid 24370860)
16. Fulle S, Belia S, Vecchiet J, Morabito C, Vecchiet L, Fano G: Modification of the functional capacity of sarcoplasmic reticulum membranes in patients suffering from chronic fatigue syndrome. Neuromuscul Disord, 2003, 13, 6, 479-484. (Pubitemid 36937124)
17. Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A et al.: Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med, 2000, 29, 1252-1259.
18. Fulle S, Pietrangelo T, Mancinelli R, Saggini R, Fanò G: Specific correlations between muscle oxidative stress and chronic fatigue syndrome: a working hypothesis. J Muscle Res Cell Motil, 2007, 28, 355-362.
19. Gerrity TR, Papanicolaou DA, Amsterdam JD, Bingham S, Grossman A, Hedrick T, Herberman RB et al.: Immunologic aspects of chronic fatigue syndrome. Neuroimmunomodulation, 2004, 11, 351-357.
20. Ghosh A, Roy A, Matras J, Brahmachari S, Grendelman HE, Pahan K: Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci, 2009, 29, 13543-13556.
21. Gornall AG, Bardawill CJ, David MM: Determination of serum proteins by means of the biuret reaction. J Biol Chem, 1949, 177, 751-766.
22. 15N nitrate in biological fluids. Ann Biochem, 1982,126, 131-138.
23. Guasti L, Marino F, Cosentino M, Maio RC, Rasini E, Ferrari M, Castiglioni L et al.: Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur Heart J, 2008, 29, 1118-1126. (Pubitemid 351844894)
24. Harvey BH, Oosthuizen F, Brand L, Wegener G, Stein DJ: Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology, 2004, 175, 494-502. (Pubitemid 39362049)
25. Heim C, Wagner D, Maloney E, Papanicolaou DA, Solomon L, Jones JF, Unger ER, Reeves WC: Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study. Arch Gen Psychiatry, 2006, 63, 1258-1266. (Pubitemid 44708084)
26. Hoglund K, Blennow K: Effect of HMG-CoA reductase inhibitors on β-amyloid peptide levels: implications for Alzheimer's disease. CNS Drugs, 2007, 21, 449-462. (Pubitemid 46849181)
27. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M: Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis, 1997, 128, 11-18. (Pubitemid 27065256)
28. Jammes Y, Steinberg JG, Mambrini O, Brégeon F, Delliaux S: Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med, 2005, 257, 299-310. (Pubitemid 40342133)
29. Kalenova LF, Sukhovei YG, Fisher TA: Specific and nonspecific reactions of mouse immune system under the effect of short term exposure in warm and/or cold water. Bull Exp Biol Med, 2005, 140, 720-722. (Pubitemid 43362058)
30. Kaur G, Kulkarni SK: Investigations on possible serotonergic involvement in effects of OB-200G (polyherbal preparation) on food intake in female mice. Eur J Nutr, 2001, 40, 127-133. (Pubitemid 32963503)
31. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ: Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med, 2005, 39, 584-589. (Pubitemid 41112100)
32. King TE: Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol, 1967, 10, 322-331.
33. King TE, Howard RL: Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol, 1967, 10, 275-284.
34. Kulkarni SK: Handbook of Experimental Pharmacology. Vallabh Prakashan, Delhi, 1999, 123-125.
35. Kumar P, Padi SS, Naidu PS, Kumar A: Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fund Clin Pharmacol, 2007, 21, 297-306. (Pubitemid 46800477)
36. Lane RJ, Barrett MC, Taylor DJ, Kemp GJ, Lodi R: Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle. Neuromusc Disord, 1998, 8, 204-209. (Pubitemid 28246118)
37. Laufs U: Beyond lipid-lowering: effects of statin on endothelial nitric oxide. Eur J Pharmacol, 2003, 58, 719-731.
38. Li X, Monks B, Ge Q, Birnbaum MJ: Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1α transcription coactivator. Nature, 2007, 447, 1012-1016. (Pubitemid 46975750)
39. Lim JH, Lee JC, Lee YH, Choi IY, Oh YK, Kim HS, Park JS, Kim WK: Simvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal. J Neurochem, 2006, 97, 140-150.
40. Liu Y, Peterson DA, Kimura H, Schubert D: Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) reduction. J Neurochem, 1997, 69:581-593. (Pubitemid 27327958)
41. Luck H: Catalase. In: Methods of Enzymatic Analysis. Ed. Bergmeyer HU, Academic Press, New York, 1971, 885-893.
42. Maes M, Mihaylova I, Kubera M, Bosmans E: Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett, 2007, 28, 463-469. (Pubitemid 47577727)
43. Mahley RW, Huang Y, Rall SC: Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res, 1999, 40, 1933-1949. (Pubitemid 29523420)
44. McCully KK, Natelson BH: Impaired oxygen delivery to muscle in chronic fatigue syndrome. Clin Sci (Lond), 1999, 97, 603-608. (Pubitemid 29527839)
45. Nomura S, Shimizu J, Kinjo M, Kametani H, Nakazawa T: A new behavioral test for antidepressant drugs. Eur J Pharmacol, 1982, 83, 171-175. (Pubitemid 12001157)
46. O'Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A: Cognitive behavioural therapy in chronic fatigue syndrome: a randomized controlled trial of an outpatient group programme. Health Technol Assess, 2006, 10, 37-43.
47. Pall ML: Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypotheses, 2002, 54, 115-125.
48. Pizzigallo E, Racciatti D, Vecchiet J: Clinical and pathophysiological aspects of chronic fatigue syndrome. J Musculoskeletal Pain, 1999, 7, 217-224. (Pubitemid 29447919)
49. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 1998, 92, 829-839. (Pubitemid 28155321)
50. Shimizu J, Nomura S, Hiroko K, Nakazawa T: Effects of water temperature and weight of wheel load on water wheel turning behaviour of imipramine administered mice. Psychopharmacology, 1984, 84, 20-21. (Pubitemid 14032201)
51. Singh IP, Chopra AK, Coppenhaver DH, Ananatharamaiah GM, Baron S: Lipoproteins account for part of the broad non-specific antiviral activity of human serum. Antiviral Res, 1999, 42, 211-218.
52. Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A: An electron transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol, 1967, 32, 415-438.
53. Stoll LL, McCormick ML, Denning GM, Weintraub NL: Antioxidant effects of statins. Drugs Today (Barc), 2004, 40, 975-990.
54. Tadokoro C, Kiuchi Y, Yamazaki Y, Nara K, Oguchi K, Kamijima K: Behavioral stimulation without alteration of β and 5-HT receptors and adenylate cyclase activity in rat brain after chronic sertraline administration. Psychopharmacology, 1997, 130, 124-130. (Pubitemid 27132757)
55. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL: Statins: mechanisms of neuroprotection. Prog Neurobiol, 2009, 88, 64-75.
56. Vaughan CJ, Delanty N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke, 1999, 30, 1969-1973. (Pubitemid 29411843)
57. Vaughan CJ, Gotto AM, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol, 2000, 35, 1-10. (Pubitemid 30061252)
58. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol, 2000, 20, 61-69. (Pubitemid 30048347)
59. Wahner AD, Bronstein JM, Bordelon YM, Ritz B: Statin use and the risk of Parkinson disease. Neurology, 2008, 70, 1418-1422. (Pubitemid 351521934)
60. Wang W, Wong CW: Statins enhance peroxisome proliferator-activated receptor gamma coactivator-1alpha activity to regulate energy metabolism. J Mol Med (Berl), 2010, 88, 309-317.
61. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, Nickenig G: Inhibition of geranyl-geranylation reduces angiotensin II mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol, 2001, 59, 646-654. (Pubitemid 32179945)
62. Wills ED: Mechanism of lipid peroxide formation in animal. Biochem J, 1966, 99, 667-676.